Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2026Anticancer Research

Clinical Outcomes of Pola-R-CHP Therapy in Patients Aged >80 Years With Diffuse Large B-Cell Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

YBYuta BabaSFSATOSHI FUKUMURASTSEIRA TANAI

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows Pola-R-CHP is effective and safe for elderly patients with DLBCL, suggesting it as a viable treatment option.

Key Points

  • This study aims to evaluate the efficacy and safety of Pola-R-CHP therapy in patients over 80 years old diagnosed with diffuse large B-cell lymphoma.
  • Retrospective analysis of 65 patients with newly diagnosed DLBCL receiving Pola-R-CHP.
  • Stratified patients by age: 49 patients ≤80 years and 16 patients >80 years.
  • Primary endpoint was progression-free survival (PFS) with secondary endpoints including overall survival (OS) and objective response rate (ORR).
  • Patients >80 years received lower doses of cyclophosphamide and doxorubicin but similar ORR (85.7% vs. 93.8%, p=0.67) and complete response rate (CRR) (79.6% vs. 75.0%, p=0.73).
  • Age >80 years was not associated with inferior PFS (HR=0.44, p=0.28), OS (HR=0.82, p=0.80), or event-free survival (EFS) (HR=1.02, p=0.96).
  • No treatment-related deaths observed, and adverse events were comparable between age groups.

Cite This Study

Baba et al. (2026) studied this question.

synapsesocial.com/papers/6a44add75cd2549c8bc43447https://doi.org/10.21873/anticanres.18264
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R- CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: A real- world study2025
  2. 2Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study2025 · 5 citations
  3. 3Real‐World Safety and Efficacy of Pola‐R‐ <scp>CHP</scp> in Previously Untreated <scp>DLBCL</scp> : <scp>POLASTAR</scp> Interim Analysis of 500 Patients2026
  4. 4Phase 2 trial of polatuzumab vedotin, rituximab and dose attenuated CHP in patients 75 years and older with large B-cell lymphoma2025
  5. 5Clinical efficacy and safety of polatuzumab vedotin, rituximab, and zanubrutinib (POLA-Z-R) therapy in treatment of super-elderly patients with DLBCL: A real-world retrospective study2025